#GynCSM Transcript
Healthcare social media transcript of the #GynCSM hashtag.
– ().
See #GynCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | GYN Cancer | #GYNCSM @gyncsm Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
 | Dee Sparacio @womenofteal RT @gyncsm: Welcome to #gyncsm - a passionate community of gynecologic cancer survivors, caregivers, advocates and health care providers. |
| GYN Cancer | #GYNCSM @gyncsm Our co-moderators are @womenofteal @btrfly12 #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We start out with brief intro’s - Please take a moment to introduce yourself. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: We start out with brief intro’s - Please take a moment to introduce yourself. #gyncsm |
 | Christina Lizaso @btrfly12 Christina Lizaso – passionate re: community engagement and cancer. I’ll be moderating as @gyncsm today. #gyncsm |
| Dee Sparacio @womenofteal Dee here! Dx #ovca Stage3B 2005, OC research advocate, blogger & co-moderator #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm If you prefer to listen only during the chat, we'd love for you to tweet "#gyncsm" when you join - just to let us know you are here. |
 | NCI Cancer Stats @NCICancerStats Check out our Did You Know? video to learn more about cervical cancer statistics here: https://t.co/UyoTcy6SNc #GynCSM |
| Dee Sparacio @womenofteal @barbara_render Please include #gyncsm in your tweets so everyone in the chat can follow. Thanks for joining us. |
| GYN Cancer | #GYNCSM @gyncsm Please continue intro's & welcomes - we'll start in w/ the "ground rules" :) and tips! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: If you prefer to listen only during the chat, we'd love for you to tweet "#gyncsm" when you join - just to let us know you are here. |
| Dee Sparacio @womenofteal @cawincolumbia Welcome . Glad to have you with us tonight! #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm The #gyncsm chat promotes community in a public forum. Learn more about risks/benefits: https://t.co/TipZUv1jQy |
| Dee Sparacio @womenofteal #gyncsm tagged resources and referrals are not a substitute for speaking with your doctor who understands your needs and history. |
| Dee Sparacio @womenofteal RT @gyncsm: The #gyncsm chat promotes community in a public forum. Learn more about risks/benefits: The #gyncsm chat promotes community in a public forum. Learn more about risks/benefits: https://t.co/TipZUv1jQy |
| GYN Cancer | #GYNCSM @gyncsm Are you new to tweet chats? Follow hashtag #gyncsm and include it in every tweet during the next hour to engage with others about this topic. |
| Dee Sparacio @womenofteal @barbara_render When we ask the questions you can RT this with the #gyncsm . |
 | Barbara Render @barbara_render @womenofteal I am 3c high grade 10 years after Dee. #gyncsm |
| Dee Sparacio @womenofteal @barbara_render Thanks for joining in tonight. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Welcome to all those gathering as well as those “listening in”. You can always tweet, DM or email us with questions/comments after the chat is over. #gyncsm |
| Dee Sparacio @womenofteal Remember - Twitter is an open social network and posts are public. Use a Direct Messages to exchange email addresses/personal info #gyncsm |
| Barbara Render @barbara_render RT @EMBOSU: You may have heard about the MAGENTA (Making Genetic testing accessible) study & now thanks to @MDAndersonNews Nadine Rayes, @karenluMD, et al. you can read an article about it! #gcchat #gyncsm #bcsm #gencsm To join the study: https://t.co/Cep5aLxEiE https://t.co/4Fy0sMPVpF |
 | Rick Boulay,MD @journeycancer RT @gyncsm: Our health care moderators are @ShannonWestin @temkins @journeycancer and our mental health moderator @DrBeckerSchutte #gyncsm |
| Dee Sparacio @womenofteal Thank you to all who have tweeted during the past month with the #gyncsm hashtag and those who RT'd about this chat #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Announcement: We hope you will join and spread the word about the all-cancer chat #CancerSM on Thur Jul 11 at 8pmET on the Basics of Biomarker Testing with @TimAllenMDJD https://t.co/SNuzxbFArc #gyncsm https://t.co/0sj9IJW3Lu |
| Dee Sparacio @womenofteal RT @gyncsm: Announcement: Announcement: We hope you will join and spread the word about the all-cancer chat #CancerSM on Thur Jul 11 at 8pmET on the Basics of Biomarker Testing with @TimAllenMDJD https://t.co/SNuzxbFArc #gyncsm https://t.co/0sj9IJW3Lu |
 | Sarah Temkin @temkins RT @gyncsm: Announcement: Announcement: We hope you will join and spread the word about the all-cancer chat #CancerSM on Thur Jul 11 at 8pmET on the Basics of Biomarker Testing with @TimAllenMDJD https://t.co/SNuzxbFArc #gyncsm https://t.co/0sj9IJW3Lu |
| Rick Boulay,MD @journeycancer RT @gyncsm: Announcement: Announcement: We hope you will join and spread the word about the all-cancer chat #CancerSM on Thur Jul 11 at 8pmET on the Basics of Biomarker Testing with @TimAllenMDJD https://t.co/SNuzxbFArc #gyncsm https://t.co/0sj9IJW3Lu |
 | Suzie Siegel @SuzieSiegel Hi, I was diagnosed with vaginal #leiomyosarcoma in 2002 & it went to my right lung twice. I try to help other #sarcoma patients. We are chatting tonight using this hashtag: #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Tonight on #gyncsm we are discussing Maintenance Therapies for Gyn Cancers. You can find a list of the upcoming topic questions on our blog page: https://t.co/t2ZjptrlKA |
 | @changingourmindset @changermindset RT @coffeemommy: THIS! So many more "precision" variables to be considered as we try to truly "personalize" treatment. cc: THIS! So many more "precision" variables to be considered as we try to truly "personalize" treatment. cc: #lcsm #bcsm #bccww #gyncsm #CancerResearch |
| Dee Sparacio @womenofteal @SuzieSiegel Hope you are doing well, Suzie. Glad you are here tonight. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Tonight on #gyncsm we are discussing Maintenance Therapies for Gyn Cancers. You can find a list of the upcoming topic questions on our blog page: https://t.co/t2ZjptrlKA |
| Rick Boulay,MD @journeycancer Hello all. Rick Boulay, Gyn Oncologist @mystlukes Bethlehem PA #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm We’ll use a Topic format tonight with T1:, T2:, etc. posed from this handle. Include the corresponding T1:, T2:, etc. at the front of your answer/comment. There are 5 Topic questions tonight followed by a Today I Learned (TIL) segment. #gyncsm |
 | Mimi @Mimiinmendon #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Here comes Topic 1 (T1:)... #gyncsm |
| Rick Boulay,MD @journeycancer @SuzieSiegel Hi Suzy. #gyncsm |
| Rick Boulay,MD @journeycancer RT @gyncsm: Tonight on #gyncsm we are discussing Maintenance Therapies for Gyn Cancers. You can find a list of the upcoming topic questions on our blog page: https://t.co/t2ZjptrlKA |
| Dee Sparacio @womenofteal @journeycancer @mystlukes Hi Rick! Glad to see you #gyncsm |
| Dee Sparacio @womenofteal @Mimiinmendon Welcome! #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: We’ll use a Topic format tonight with T1:, T2:, etc. posed from this handle. Include the corresponding T1:, T2:, etc. at the front of your answer/comment. There are 5 Topic questions tonight followed by a Today I Learned (TIL) segment. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T1: What are maintenance therapies and why are they used? #gyncsm |
| Suzie Siegel @SuzieSiegel RT @gyncsm: Tonight on #gyncsm we are discussing Maintenance Therapies for Gyn Cancers. You can find a list of the upcoming topic questions on our blog page: https://t.co/t2ZjptrlKA |
| Dee Sparacio @womenofteal RT @gyncsm: T1: T1: What are maintenance therapies and why are they used? #gyncsm |
| Rick Boulay,MD @journeycancer @womenofteal @mystlukes Nice to see you Dee. #gyncsm |
| Dee Sparacio @womenofteal @theNCI def: maintenance therapy is given to help keep cancer from coming back after it has disappeared following the initial therapy. It may include treatment with drugs, vaccines, or antibodies that kill cancer cells, and it may be given for a long time. #gyncsm |
| Christina Lizaso @btrfly12 NCI: maintenance therapy is treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy. It may include treatment with drugs, vaccines, or antibodies that kill cancer cells, and it may be given for a long time. #gyncsm |
 | Gregg Nelson @GreggNelsonERAS #SoMe4GynOnc |
| NCI Cancer Stats @NCICancerStats Localized #VulvarCancer has an 86.3% 5-year relative survival rate. Get more facts here: https://t.co/lpL0PJT7LW #GynCSM https://t.co/jqzjLHLF6U |
 | Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN Hi all, sorry to be late to arrive. I’m Grace, cancer rehab nurse researcher working in Gyn Oncology. #gyncsm |
| Rick Boulay,MD @journeycancer A1 Maintenance therapies are additional chemotherapy given beyond the standard chemotherapy. The philosophy is based on treatment for hematologic cancers and is now used for some solid tumors. The hope is that the additional treatment will prevent or delay recurrences. #gyncsm |
 | Joseph Steward @jsteward2930 RT @NCICancerStats: Localized #VulvarCancer has an 86.3% 5-year relative survival rate. Get more facts here: Localized #VulvarCancer has an 86.3% 5-year relative survival rate. Get more facts here: https://t.co/lpL0PJT7LW #GynCSM https://t.co/jqzjLHLF6U |
| Christina Lizaso @btrfly12 #gyncsm: |
| Dee Sparacio @womenofteal @GraceCampbellRN Hi Grace, Glad you could join us.#gyncsm |
| Rick Boulay,MD @journeycancer RT @womenofteal: @theNCI def: @theNCI def: maintenance therapy is given to help keep cancer from coming back after it has disappeared following the initial therapy. It may include treatment with drugs, vaccines, or antibodies that kill cancer cells, and it may be given for a long time. #gyncsm |
| Sarah Temkin @temkins The goal of maintenance therapy is to prevent recurrence or increase the time to next therapy with less side effects than chemotherapy #gyncsm |
| Dee Sparacio @womenofteal RT @journeycancer: A1 Maintenance therapies are additional chemotherapy given beyond the standard chemotherapy. The philosophy is based on treatment for hematologic cancers and is now used for some solid tumors. The hope is that the additional treatment will prevent or delay recurrences. #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: The goal of maintenance therapy is to prevent recurrence or increase the time to next therapy with less side effects than chemotherapy #gyncsm |
| Christina Lizaso @btrfly12 Two types of agents—PARP inhibitors and bevacizumab—have been FDA approved for use as maintenance therapy in women w/ advanced ovarian, fallopian & primary peritoneal #gyncsm https://t.co/DNA0tsgoeN |
| Barbara Render @barbara_render @gyncsm Biosimilars are easy iv treatments. Bev is for ova. Zir just got approved by FDA for met cervical cancer. #gyncsm |
| Rick Boulay,MD @journeycancer RT @btrfly12: Two types of agents—PARP inhibitors and bevacizumab—have been FDA approved for use as maintenance therapy in women w/ advanced ovarian, fallopian & primary peritoneal #gyncsm https://t.co/DNA0tsgoeN |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @womenofteal: @theNCI def: @theNCI def: maintenance therapy is given to help keep cancer from coming back after it has disappeared following the initial therapy. It may include treatment with drugs, vaccines, or antibodies that kill cancer cells, and it may be given for a long time. #gyncsm |
| Sarah Temkin @temkins The downside of maintenance therapy is that patients may experience toxicity and a decriment in quality of life while on a maintenance program. #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @temkins: The goal of maintenance therapy is to prevent recurrence or increase the time to next therapy with less side effects than chemotherapy #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Topic 2 - in two parts (a,b) coming up... #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @btrfly12: Two types of agents—PARP inhibitors and bevacizumab—have been FDA approved for use as maintenance therapy in women w/ advanced ovarian, fallopian & primary peritoneal #gyncsm https://t.co/DNA0tsgoeN |
| Dee Sparacio @womenofteal RT @btrfly12: Two types of agents—PARP inhibitors and bevacizumab—have been FDA approved for use as maintenance therapy in women w/ advanced ovarian, fallopian & primary peritoneal #gyncsm https://t.co/DNA0tsgoeN |
| GYN Cancer | #GYNCSM @gyncsm T2A: What evidence was there to approve Avastin (Bevacizumab) for maintenance? #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @temkins: The downside of maintenance therapy is that patients may experience toxicity and a decriment in quality of life while on a maintenance program. #gyncsm |
| Dee Sparacio @womenofteal @temkins Yes - When I was in initial treatment they were giving monthly taxol maintenance. Neuropathy was an issue. #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: The downside of maintenance therapy is that patients may experience toxicity and a decriment in quality of life while on a maintenance program. #gyncsm |
| Barbara Render @barbara_render @gyncsm Gotta go. #gyncsm |
| Suzie Siegel @SuzieSiegel RT @journeycancer: A1 Maintenance therapies are additional chemotherapy given beyond the standard chemotherapy. The philosophy is based on treatment for hematologic cancers and is now used for some solid tumors. The hope is that the additional treatment will prevent or delay recurrences. #gyncsm |
| Christina Lizaso @btrfly12 RT @temkins: The downside of maintenance therapy is that patients may experience toxicity and a decriment in quality of life while on a maintenance program. #gyncsm |
| Christina Lizaso @btrfly12 RT @temkins: The goal of maintenance therapy is to prevent recurrence or increase the time to next therapy with less side effects than chemotherapy #gyncsm |
| Rick Boulay,MD @journeycancer Numerous clinical trials from American and European consortiums have demonstrated benefit of bevacizumab in the maintenance setting in Gyn cancers. (Gog252 |
| Dee Sparacio @womenofteal RT @gyncsm: T2A: T2A: What evidence was there to approve Avastin (Bevacizumab) for maintenance? #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T2B: How long is Bev given? What side effects may women experience with maintenance Bev? Is Bev limited to women with a BRCA mutation? #gyncsm |
 | CancerDotNet @CancerDotNet T1: Maintenance therapy is the treatment of cancer with medication, typically following an initial round of treatment. Maintenance treatment may include chemotherapy, hormonal therapy, or targeted therapy: https://t.co/aK2GNv00Ot #gyncsm |
| Dee Sparacio @womenofteal T2A FDA Approval was based on GOG-0218 a multicenter, randomized, double-blind, placebo-controlled, three-arm study w/ addition of bev to carbo Taxol for patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer #gyncsm |
| Mimi @Mimiinmendon @gyncsm T1: Stage 2A FTC, grade 3. 6 years out. Was not aware of maintenance therapies for GYN cancers. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T2B: T2B: How long is Bev given? What side effects may women experience with maintenance Bev? Is Bev limited to women with a BRCA mutation? #gyncsm |
| Rick Boulay,MD @journeycancer Numerous clinical trials from American and European consortiums have demonstrated benefit of bevacizumab in the maintenance setting in Gyn cancers. (Gog252) #gyncsm |
| Dee Sparacio @womenofteal RT @CancerDotNet: T1: T1: Maintenance therapy is the treatment of cancer with medication, typically following an initial round of treatment. Maintenance treatment may include chemotherapy, hormonal therapy, or targeted therapy: https://t.co/aK2GNv00Ot #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm #gyncsm: |
| Sarah Temkin @temkins @womenofteal Neuropathy was the reason that Taxol maintenance did not become a standard of care after 2 clinical trials in ovarian cancer. Also the initial benefit seen in survival was no longer apparent after patients were followed for longer time periods #gyncsm |
| Dee Sparacio @womenofteal RT @journeycancer: Numerous clinical trials from American and European consortiums have demonstrated benefit of bevacizumab in the maintenance setting in Gyn cancers. (Gog252) #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: @womenofteal Neuropathy was the reason that Taxol maintenance did not become a standard of care after 2 clinical trials in ovarian cancer. Also the initial benefit seen in survival was no longer apparent after patients were followed for longer time periods #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @womenofteal: T2A FDA Approval was based on GOG-0218 a multicenter, randomized, double-blind, placebo-controlled, three-arm study w/ addition of bev to carbo Taxol for patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer #gyncsm |
| Christina Lizaso @btrfly12 With recurrence rates high in ovarian cancer, tough decisions on accepting side effects from maintenance therapies and also not getting treatment break #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @temkins: @womenofteal Neuropathy was the reason that Taxol maintenance did not become a standard of care after 2 clinical trials in ovarian cancer. Also the initial benefit seen in survival was no longer apparent after patients were followed for longer time periods #gyncsm |
| Sarah Temkin @temkins A2B in the US trial bevacizumab was given as maintenance for 15 cycles 3 weeks apart. Although an initial survival benefit was seen this was not sustained with longer followup. A similar trial was conducted in Europe with similar results. #gyncsm |
| Rick Boulay,MD @journeycancer In the maintenance phase, bevacizumab can be given up to an extra year of treatment. It is still unclear whether we should be giving this longer as no clinical trials have administered the drug longer than this. I have a personally treated patients for many years.#gyncsm |
| Sarah Temkin @temkins RT @btrfly12: With recurrence rates high in ovarian cancer, tough decisions on accepting side effects from maintenance therapies and also not getting treatment break #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @journeycancer: Numerous clinical trials from American and European consortiums have demonstrated benefit of bevacizumab in the maintenance setting in Gyn cancers. (Gog252) #gyncsm |
| Rick Boulay,MD @journeycancer RT @womenofteal: T2A FDA Approval was based on GOG-0218 a multicenter, randomized, double-blind, placebo-controlled, three-arm study w/ addition of bev to carbo Taxol for patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer #gyncsm |
| Rick Boulay,MD @journeycancer RT @Mimiinmendon: @gyncsm T1: @gyncsm T1: Stage 2A FTC, grade 3. 6 years out. Was not aware of maintenance therapies for GYN cancers. #gyncsm |
| Christina Lizaso @btrfly12 RT @temkins: A2B in the US trial bevacizumab was given as maintenance for 15 cycles 3 weeks apart. Although an initial survival benefit was seen this was not sustained with longer followup. A similar trial was conducted in Europe with similar results. #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @temkins: A2B in the US trial bevacizumab was given as maintenance for 15 cycles 3 weeks apart. Although an initial survival benefit was seen this was not sustained with longer followup. A similar trial was conducted in Europe with similar results. #gyncsm |
| Dee Sparacio @womenofteal Important considerations. #gyncsm |
| CancerDotNet @CancerDotNet @gyncsm T1: Maintenance therapy is the treatment of cancer with medication, typically following an initial round of treatment. Maintenance treatment may include chemotherapy, hormonal therapy, or targeted therapy: https://t.co/RGBVCDbGjn… #gyncsm |
| Christina Lizaso @btrfly12 #gyncsm: |
| Dee Sparacio @womenofteal RT @temkins: A2B in the US trial bevacizumab was given as maintenance for 15 cycles 3 weeks apart. Although an initial survival benefit was seen this was not sustained with longer followup. A similar trial was conducted in Europe with similar results. #gyncsm |
| Suzie Siegel @SuzieSiegel For anyone with gyn #sarcoma: Bevacizumab (Avastin) failed in a study of women with uterine #leiomyosarcoma, but some doctors are considering other combinations with it. #gyncsm |
| Rick Boulay,MD @journeycancer #Gyncsm Most Maintenance treatment is given for advanced disease, stage is 3 to 4. |
 | Elizabeth L. Dickson, MD, FACOG @edicksonMD @temkins #gyncsm this is what I struggle with—the overall survival benefit. And if #qualityoflife is compromised....? |
| Christina Lizaso @btrfly12 If you are tolerating maintenance well, I think the decision to stop would be hard - especially given a lack of data either way. #gyncsm |
| Sarah Temkin @temkins A2B Bevacizumab is generally well tolerated - some patients may have high blood pressure or kidney problems. More severe side effects are rare but possible. #gyncsm |
| Dee Sparacio @womenofteal @temkins So there were PFS benefits but the recent study results for OS were not there? Do you think recommendations will change? #gyncsm |
| Christina Lizaso @btrfly12 RT @SuzieSiegel: For anyone with gyn #sarcoma: For anyone with gyn #sarcoma: Bevacizumab (Avastin) failed in a study of women with uterine #leiomyosarcoma, but some doctors are considering other combinations with it. #gyncsm |
| Dee Sparacio @womenofteal RT @SuzieSiegel: For anyone with gyn #sarcoma: For anyone with gyn #sarcoma: Bevacizumab (Avastin) failed in a study of women with uterine #leiomyosarcoma, but some doctors are considering other combinations with it. #gyncsm |
| Christina Lizaso @btrfly12 RT @CancerDotNet: @gyncsm T1: @gyncsm T1: Maintenance therapy is the treatment of cancer with medication, typically following an initial round of treatment. Maintenance treatment may include chemotherapy, hormonal therapy, or targeted therapy: https://t.co/RGBVCDbGjn… #gyncsm |
| Dee Sparacio @womenofteal RT @journeycancer: #Gyncsm Most Maintenance treatment is given for advanced disease, stage is 3 to 4. |
| Dee Sparacio @womenofteal RT @temkins: A2B Bevacizumab is generally well tolerated - some patients may have high blood pressure or kidney problems. More severe side effects are rare but possible. #gyncsm |
| Christina Lizaso @btrfly12 Acronyms: OS = Overall Survival and PFS = Progression Free Survival #gyncsm :) |
| Rick Boulay,MD @journeycancer This is what we all struggle with. The benefits of maintenance therapy have to outweigh the risks. #gyncsm |
| Dee Sparacio @womenofteal @edicksonMD @temkins If used as maintenance would they be available later for recurrence ? #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T3A: PARP inhibitors were approved for recurrent ovarian cancer and now for maintenance therapy for women with the BRCA mutation. What study results led to the FDA approval? #gyncsm |
| Elizabeth L. Dickson, MD, FACOG @edicksonMD At #ASCO19 @Atul_Gawande spoke on asking patients about THEIR goals. This is the key with maintenance—what does your patient want? What is their goal? #gyncsm @Aurora_Cancer |
| Dee Sparacio @womenofteal RT @gyncsm: T3A: T3A: PARP inhibitors were approved for recurrent ovarian cancer and now for maintenance therapy for women with the BRCA mutation. What study results led to the FDA approval? #gyncsm |
| Dee Sparacio @womenofteal Yes agree 100%! #gyncsm |
| Sarah Temkin @temkins @womenofteal Bevacizumab as maintenance is another therapy available for select women with #ovariancancer. Recommendations must be personalized to a specific patient (getting the right drug to the right patient at the right time). #gyncsm |
| Christina Lizaso @btrfly12 RT @edicksonMD: At #ASCO19 @Atul_Gawande spoke on asking patients about THEIR goals. This is the key with maintenance—what does your patient want? What is their goal? #gyncsm @Aurora_Cancer |
| Christina Lizaso @btrfly12 #gyncsm : |
 | Lisa✌🏻⚜️☘️ @lglmoss RT @btrfly12: With recurrence rates high in ovarian cancer, tough decisions on accepting side effects from maintenance therapies and also not getting treatment break #gyncsm |
| Sarah Temkin @temkins RT @edicksonMD: At #ASCO19 @Atul_Gawande spoke on asking patients about THEIR goals. This is the key with maintenance—what does your patient want? What is their goal? #gyncsm @Aurora_Cancer |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN Providers: how do you assess “benefit” and risks in terms of QOL and function when helping patients decide whether to continue with maintenance? What does that thought process and conversation look like? #gyncsm |
| Rick Boulay,MD @journeycancer Physicians dont give patients the option of continuing extended maintenance therapy beyond the standard one year. The data clearly shows after discontinuation of bevacizumab recurrences begin at about three months. I offer treatment longer if patients are tolerating it #gyncsm |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @gyncsm: Announcement: Announcement: We hope you will join and spread the word about the all-cancer chat #CancerSM on Thur Jul 11 at 8pmET on the Basics of Biomarker Testing with @TimAllenMDJD https://t.co/SNuzxbFArc #gyncsm https://t.co/0sj9IJW3Lu |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @edicksonMD: At #ASCO19 @Atul_Gawande spoke on asking patients about THEIR goals. This is the key with maintenance—what does your patient want? What is their goal? #gyncsm @Aurora_Cancer |
| Dee Sparacio @womenofteal RT @GraceCampbellRN: Providers: Providers: how do you assess “benefit” and risks in terms of QOL and function when helping patients decide whether to continue with maintenance? What does that thought process and conversation look like? #gyncsm |
| Christina Lizaso @btrfly12 T3: You can get an overview of PARP inhibitors for maintenance therapy of ovarian cancer via @FacingOurRisk site https://t.co/DNA0tsgoeN #gyncsm |
| Elizabeth L. Dickson, MD, FACOG @edicksonMD Differing ideologies when it comes to maintenance. What is right for each patient? Is a treatment break what they need? Are they tolerating maintenance and have more peace of mind on it? Do they have a mutation which shows more benefit? #gyncsm |
| Dee Sparacio @womenofteal @cawincolumbia @edicksonMD @temkins So you experienced a build up of side effects and reduced QOL with PARP as with Chemo . I wasn't aware of that . #gyncsm |
| Dee Sparacio @womenofteal RT @btrfly12: T3: T3: You can get an overview of PARP inhibitors for maintenance therapy of ovarian cancer via @FacingOurRisk site https://t.co/DNA0tsgoeN #gyncsm |
| Dee Sparacio @womenofteal RT @edicksonMD: Differing ideologies when it comes to maintenance. What is right for each patient? Is a treatment break what they need? Are they tolerating maintenance and have more peace of mind on it? Do they have a mutation which shows more benefit? #gyncsm |
 | Julian Schink, MD @DrJulianSchink RT @temkins: A2B in the US trial bevacizumab was given as maintenance for 15 cycles 3 weeks apart. Although an initial survival benefit was seen this was not sustained with longer followup. A similar trial was conducted in Europe with similar results. #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @btrfly12: T3: T3: You can get an overview of PARP inhibitors for maintenance therapy of ovarian cancer via @FacingOurRisk site https://t.co/DNA0tsgoeN #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T3B: How long is PARP given during maintenance? What side effects may women experience? #gyncsm |
| Julian Schink, MD @DrJulianSchink RT @gyncsm: T3A: T3A: PARP inhibitors were approved for recurrent ovarian cancer and now for maintenance therapy for women with the BRCA mutation. What study results led to the FDA approval? #gyncsm |
| Dee Sparacio @womenofteal T3A One study used was phase III SOLO1 trial (NCT01844986) assessed maintenance olaparib/placebo treatment following first-line platinum-based chemotherapy #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T3B: T3B: How long is PARP given during maintenance? What side effects may women experience? #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @gyncsm: T3B: T3B: How long is PARP given during maintenance? What side effects may women experience? #gyncsm |
| Sarah Temkin @temkins @womenofteal @cawincolumbia @edicksonMD Not for everyone - which makes this difficult. Most patients tolerate these medications very well. There is no way to predict who will have side effects. #gyncsm. |
| Elizabeth L. Dickson, MD, FACOG @edicksonMD @womenofteal @cawincolumbia @temkins #gyncsm @womenofteal after our talk I met with several patients where the GI side effects of a PARP were enough to want to stop the drug. Another had eye changes. These are so new—who knows what we will find! |
| Dee Sparacio @womenofteal RT @edicksonMD: @womenofteal @cawincolumbia @temkins #gyncsm @womenofteal after our talk I met with several patients where the GI side effects of a PARP were enough to want to stop the drug. Another had eye changes. These are so new—who knows what we will find! |
| Dee Sparacio @womenofteal T3A Frontline maintenance olaparib treatment was approved by the FDA in December 2018 for BRCAm carriers. #gyncsm |
| Dee Sparacio @womenofteal @cawincolumbia @edicksonMD @temkins Sorry you are having that experience. Did you start taking it on a trial and then continued on it? #gyncsm |
| Sarah Temkin @temkins RT @womenofteal: T3A One study used was phase III SOLO1 trial (NCT01844986) assessed maintenance olaparib/placebo treatment following first-line platinum-based chemotherapy #gyncsm |
| Elizabeth L. Dickson, MD, FACOG @edicksonMD T3B: PARP truly can be used until progression, or side effects make the patients want to stop. Biggest SE I see are GI and heme (bone marrow). Some recent eye changes...which is a new one!! #gyncsm |
| Dee Sparacio @womenofteal T3B: How long is PARP given during maintenance? What side effects may women experience? #gyncsm |
| Dee Sparacio @womenofteal RT @edicksonMD: T3B: T3B: PARP truly can be used until progression, or side effects make the patients want to stop. Biggest SE I see are GI and heme (bone marrow). Some recent eye changes...which is a new one!! #gyncsm |
| Rick Boulay,MD @journeycancer Clinical trials proves a 21 month progression free survival for each of the PARP inhibitors: olaparib, rucaparib, Mira Pam in #gyncsm |
| Dee Sparacio @womenofteal RT @journeycancer: Clinical trials proves a 21 month progression free survival for each of the PARP inhibitors: Clinical trials proves a 21 month progression free survival for each of the PARP inhibitors: olaparib, rucaparib, Mira Pam in #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm T4: Are maintenance drugs given for other gyn cancers? Cervical, endometrial, etc? #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T4: T4: Are maintenance drugs given for other gyn cancers? Cervical, endometrial, etc? #gyncsm |
| Rick Boulay,MD @journeycancer Risks and benefits here are best defined by the patient. And what the individual patient is willing to tolerate for extended life. This is a unique conversation between the clinician and each patient. #gyncsm |
| Sarah Temkin @temkins T3B the length of parp maintenance will depend on the clinical scenario (up front or recurrent) as well as the patient's tolerance to the medications #gyncsm |
| Dee Sparacio @womenofteal @journeycancer And an important conversation to have! #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: T3B the length of parp maintenance will depend on the clinical scenario (up front or recurrent) as well as the patient's tolerance to the medications #gyncsm |
 | Bob Tufts @TuftsB @btrfly12 You are an n of 1. If maintenance is working for you and holding cancer at bay, stick with it. #gyncsm |
| Dee Sparacio @womenofteal T4 No maintenance strategies are currently approved for endometrial cancer #gyncsm |
| Rick Boulay,MD @journeycancer The treatment is generally given until either the disease progresses where the patient cannot tolerate side effect. The side effects are different among each of the agents but generally fall into the realms of low blood counts, fatigue, nausea, in general malaise. #gyncsm |
| Christina Lizaso @btrfly12 For all that AI has the potential to bring in healthcare, it is still going to be about building trust and a positive doctor-patient relationship. #gyncsm |
| Rick Boulay,MD @journeycancer RT @gyncsm: T4: T4: Are maintenance drugs given for other gyn cancers? Cervical, endometrial, etc? #gyncsm |
| Dee Sparacio @womenofteal T4 but a trial evaluated carboplatin and paclitaxel for six cycles with and without trastuzumab in high-grade serous endometrial cancer with Her2/neu overexpression.The study demonstrated a significant improvement in PFS Time will tell if OS will also improve #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @btrfly12: For all that AI has the potential to bring in healthcare, it is still going to be about building trust and a positive doctor-patient relationship. #gyncsm |
| Rick Boulay,MD @journeycancer Yes. Maintenance with bevacizumab is standard for cervical and endometrial cancers as well as ovarian/fallopian tube/primary peritoneal cancers. #gyncsm |
| Elizabeth L. Dickson, MD, FACOG @edicksonMD T4: No maintenance for Endometrial or Cervical—Except in those with mutations that they can use Keytruda—which is “kinda of” a maintenance #gyncsm @Aurora_Cancer |
| GYN Cancer | #GYNCSM @gyncsm T5: What questions should a patient ask when offered a maintenance therapy? #gyncsm |
| Dee Sparacio @womenofteal RT @journeycancer: Yes. Maintenance with bevacizumab is standard for cervical and endometrial cancers as well as ovarian/fallopian tube/primary peritoneal cancers. #gyncsm |
| Dee Sparacio @womenofteal You can find excellent info ( some shared in this chat) on Maintenance therapies in @ASCO Ed book Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers https://t.co/7CVKCO8OJe #gyncsm |
| Dee Sparacio @womenofteal @ASCO This was a very interesting session at #ASCO19 #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @womenofteal: You can find excellent info ( some shared in this chat) on Maintenance therapies in @ASCO Ed book Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers https://t.co/7CVKCO8OJe #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: T5: T5: What questions should a patient ask when offered a maintenance therapy? #gyncsm |
| Rick Boulay,MD @journeycancer Am I a good candidate for maintenance therapy? Which maintenance therapy is best for my cancer? How will we know when is the right time to stop treatment? #gyncsm |
| Sarah Temkin @temkins This is a great publication #gyncsm |
| Rick Boulay,MD @journeycancer RT @womenofteal: You can find excellent info ( some shared in this chat) on Maintenance therapies in @ASCO Ed book Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers https://t.co/7CVKCO8OJe #gyncsm |
| Dee Sparacio @womenofteal RT @journeycancer: Am I a good candidate for maintenance therapy? Which maintenance therapy is best for my cancer? How will we know when is the right time to stop treatment? #gyncsm |
| Christina Lizaso @btrfly12 RT @womenofteal: You can find excellent info ( some shared in this chat) on Maintenance therapies in @ASCO Ed book Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers https://t.co/7CVKCO8OJe #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Time to share any closing thoughts on tonight's Maintenance Therapy topic. You can start your tweet w/ TIL: for Today I Learned. Thanks so much for all the great knowledge shared on this chat. #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @journeycancer: Am I a good candidate for maintenance therapy? Which maintenance therapy is best for my cancer? How will we know when is the right time to stop treatment? #gyncsm |
| Rick Boulay,MD @journeycancer RT @gyncsm: Time to share any closing thoughts on tonight's Maintenance Therapy topic. You can start your tweet w/ TIL: Time to share any closing thoughts on tonight's Maintenance Therapy topic. You can start your tweet w/ TIL: for Today I Learned. Thanks so much for all the great knowledge shared on this chat. #gyncsm |
| Suzie Siegel @SuzieSiegel T4. Some women with gyn #leiomyosarcoma use #trabectedin (#Yondelis) as maintenance therapy. They and women with endometrial stromal #sarcoma may use hormone therapy. (I took an aromatase inhibitor for about 5 years.) #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Thanks to everyone for joining along. Our next #gyncsm chat will be Wed Aug 14th on Finding Balance: “Cancer Life” vs. “Real Life”. |
| Dee Sparacio @womenofteal T5 Some I would ask include: what are the side effects of long term use of the treatment? Will I be able to use this again if I recur? How much is the cost? And will my insurance cover it? #gyncsm |
| Elizabeth L. Dickson, MD, FACOG @edicksonMD Yes! Check this out. Great discussion of maintenance therapies and the different ideologies behind the discussion #gyncsm @Aurora_Cancer |
| Dee Sparacio @womenofteal RT @SuzieSiegel: T4. Some women with gyn #leiomyosarcoma use #trabectedin (#Yondelis) as maintenance therapy. They and women with endometrial stromal #sarcoma may use hormone therapy. (I took an aromatase inhibitor for about 5 years.) #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Thanks to everyone for joining along. Our next #gyncsm chat will be Wed Aug 14th on Finding Balance: Thanks to everyone for joining along. Our next #gyncsm chat will be Wed Aug 14th on Finding Balance: “Cancer Life” vs. “Real Life”. |
| Rick Boulay,MD @journeycancer I am greatful for Dee and Christina’s leadership in developing and maintaining this wonderful group. Thank you for the service that you provide to our patients. #gyncsm |
| Sarah Temkin @temkins Cost can be a real burden with maintenance therapies. Important to ask so that risks and benefits can be weighed. #gyncsm |
| Rick Boulay,MD @journeycancer RT @SuzieSiegel: T4. Some women with gyn #leiomyosarcoma use #trabectedin (#Yondelis) as maintenance therapy. They and women with endometrial stromal #sarcoma may use hormone therapy. (I took an aromatase inhibitor for about 5 years.) #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Please join/share the all-cancer chat #CancerSM Thur Jul 11 at 8pmET on the Basics of Biomarker Testing with @TimAllenMDJD https://t.co/SNuzxbFArc #gyncsm https://t.co/V5yrBREAtJ |
| Rick Boulay,MD @journeycancer Great topic #gyncsm |
| Christina Lizaso @btrfly12 RT @womenofteal: T5 Some I would ask include: T5 Some I would ask include: what are the side effects of long term use of the treatment? Will I be able to use this again if I recur? How much is the cost? And will my insurance cover it? #gyncsm |
| Rick Boulay,MD @journeycancer RT @womenofteal: T5 Some I would ask include: T5 Some I would ask include: what are the side effects of long term use of the treatment? Will I be able to use this again if I recur? How much is the cost? And will my insurance cover it? #gyncsm |
| Dee Sparacio @womenofteal @journeycancer Thank you for being with us for 5+ years. We appreciate your support and the info you provide to our community. #gyncsm |
| Dee Sparacio @womenofteal RT @temkins: Cost can be a real burden with maintenance therapies. Important to ask so that risks and benefits can be weighed. #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @gyncsm: Thanks to everyone for joining along. Our next #gyncsm chat will be Wed Aug 14th on Finding Balance: Thanks to everyone for joining along. Our next #gyncsm chat will be Wed Aug 14th on Finding Balance: “Cancer Life” vs. “Real Life”. |
| Dee Sparacio @womenofteal RT @gyncsm: Please join/share the all-cancer chat #CancerSM Thur Jul 11 at 8pmET on the Basics of Biomarker Testing with @TimAllenMDJD https://t.co/SNuzxbFArc #gyncsm https://t.co/V5yrBREAtJ |
| Rick Boulay,MD @journeycancer Good night everyone! Thank you. #gyncsm |
| Suzie Siegel @SuzieSiegel T5. Women with gyn #leiomyosarcoma should ask to see the evidence for aromatase inhibitors, not just accept anecdotal information. For example, the fact that I did it is not proof it worked. #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Thanks again for joining. As always, remember to tweet things of interest with hashtag #gyncsm to keep the conversation going between chats. |
| Dee Sparacio @womenofteal TIL that the conversation you may have with your gyn onc about maintenance therapies is an important one and there are many things to consider in making your decision. #gyncsm |
| Rick Boulay,MD @journeycancer RT @SuzieSiegel: T5. Women with gyn #leiomyosarcoma should ask to see the evidence for aromatase inhibitors, not just accept anecdotal information. For example, the fact that I did it is not proof it worked. #gyncsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tomorrow #cancersm |
| Dee Sparacio @womenofteal RT @SuzieSiegel: T5. Women with gyn #leiomyosarcoma should ask to see the evidence for aromatase inhibitors, not just accept anecdotal information. For example, the fact that I did it is not proof it worked. #gyncsm |
| Dee Sparacio @womenofteal RT @gyncsm: Thanks again for joining. As always, remember to tweet things of interest with hashtag #gyncsm to keep the conversation going between chats. |
| Dee Sparacio @womenofteal Grateful for our #gyncsm co-moderators! @btrfly12 @ShannonWestin @temkins @journeycancer @DrBeckerSchutte #gyncsm |
| Dr. Grace Campbell, PhD, MSW, RN, CRRN, FARN @GraceCampbellRN RT @womenofteal: TIL that the conversation you may have with your gyn onc about maintenance therapies is an important one and there are many things to consider in making your decision. #gyncsm |
| Dee Sparacio @womenofteal Remember to check https://t.co/Df2f7Okp35 for a transcript of the chat and resources #gyncsm |
| Sarah Temkin @temkins RT @womenofteal: Grateful for our #gyncsm co-moderators! @btrfly12 @ShannonWestin @temkins @journeycancer @DrBeckerSchutte #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm Great to see familiar and new faces along for tonight's #gyncsm Have a great evening and check our blog for a recap and links https://t.co/oAfi7Me49e |
| Dee Sparacio @womenofteal Thank you @barbarapender @cawincolumbia and @SuzieSiegel for sharing your experience and insights with us.#gyncsm |
| Christina Lizaso @btrfly12 RT @womenofteal: TIL that the conversation you may have with your gyn onc about maintenance therapies is an important one and there are many things to consider in making your decision. #gyncsm |
| Dee Sparacio @womenofteal Additional info NCCN updates from annual conference re: bev and parps https://t.co/FXeNKN3T2Z #gyncsm |
| Elizabeth L. Dickson, MD, FACOG @edicksonMD @journeycancer @womenofteal @btrfly12 I agree! You are both amazing! #gyncsm |
| Dee Sparacio @womenofteal And lastly a resource on costs of maintenance therapies Cost of maintenance therapies https://t.co/DDXl2BQV6R #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm RT @womenofteal: Additional info NCCN updates from annual conference re: Additional info NCCN updates from annual conference re: bev and parps https://t.co/FXeNKN3T2Z #gyncsm |
| Sarah Temkin @temkins RT @womenofteal: And lastly a resource on costs of maintenance therapies Cost of maintenance therapies https://t.co/DDXl2BQV6R #gyncsm |
| Sarah Temkin @temkins RT @womenofteal: Additional info NCCN updates from annual conference re: Additional info NCCN updates from annual conference re: bev and parps https://t.co/FXeNKN3T2Z #gyncsm |
| Christina Lizaso @btrfly12 Thanks so much @womenofteal for all your research and preparation for tonight's topic. And thank you to all our healthcare professionals for sharing of your time. #gyncsm |
| Dee Sparacio @womenofteal I'm excited about next months chat and I hope many will join #gyncsm - Wed Aug 14th on Finding Balance: “Cancer Life” vs. “Real Life”. #gyncsm |
| CancerDotNet @CancerDotNet T5: Consider asking these questions: Is maintenance therapy an option for me? What type of maintenance therapy do you recommend? What are the potential benefits and risks of this treatment? How often would I get it? For how long? Read more: https://t.co/aK2GNv00Ot #gyncsm |
| GYN Cancer | #GYNCSM @gyncsm RT @CancerDotNet: T5: T5: Consider asking these questions: Is maintenance therapy an option for me? What type of maintenance therapy do you recommend? What are the potential benefits and risks of this treatment? How often would I get it? For how long? Read more: https://t.co/aK2GNv00Ot #gyncsm |
| Dee Sparacio @womenofteal RT @CancerDotNet: T5: T5: Consider asking these questions: Is maintenance therapy an option for me? What type of maintenance therapy do you recommend? What are the potential benefits and risks of this treatment? How often would I get it? For how long? Read more: https://t.co/aK2GNv00Ot #gyncsm |
| Dee Sparacio @womenofteal @CancerDotNet Thanks for joining in tonight! appreciate it. #gyncsm |
#GynCSM content from Twitter.